Sonoma Pharmaceuticals Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa
March 30 2022 - 6:00AM
Business Wire
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare
leader developing and producing patented Microcyn® technology based
stabilized hypochlorous acid (HOCl) products for a wide range of
applications, including wound, eye, oral and nasal care, and
dermatological conditions, today announced that it has launched
Microdox®, an urinary tract infection catheter and bladder rinse in
New Zealand, Australia and South Africa.
Microdox® is a super-oxidized solution based on Sonoma’s
patented Microcyn® Technology intended to treat and prevent
infections in the urinary tract and bladder. Microdox® is a
non-irritating and non-toxic solution and is ready for immediate
use. Microdox® is currently available through Sonoma’s partners, Te
Arai BioFarma in New Zealand and Australia, and NuAngle in South
Africa.
“We believe Microdox® is a unique bladder irrigation that
fulfils the requirements of an effective adjunct UTI prevention and
treatment for the removal of UTI-causing bacteria, bacterial
biofilms and drug-resistant strains,” said Scott Lissington, COO of
Te Arai BioFarma.
“We look forward to the benefits that Microdox® will offer in
the prevention and treatment of urinary tract infections to health
care professionals. This is a revolutionary treatment to patients
that have been struggling with complicated, antibiotic resistant
and recurrent UTIs,” said Lindsay Shahim, Director of NuAngle.
“We are pleased to bring our partners this new indication for
Microdox® that will help reduce urinary tract infections for their
patients. Through the science and development of Microcyn®
Technology our aim is to improve the quality of life for patients,
including those that require a bladder and catheter rinse,” said
Bruce Thornton, COO of Sonoma Pharmaceuticals. “Our proprietary
Microcyn® technology is truly the next-generation formulation in
terms of superior antimicrobial impact, shelf stability and
safety.”
About Te Arai BioFarma Ltd.
Te Arai BioFarma Limited is a privately owned New Zealand and
Australian company specializing in medical devices and specialty
medicines. We aim to improve health and productivity through the
affordable control and prevention of disease. Te Arai BioFarma is
committed to maintaining long term collaborative and innovative
relationships with significant global suppliers of health products.
Through partnering with leading suppliers both locally and
internationally, Te Arai BioFarma is committed to ensuring the
highest standard of care is taken in bringing products from these
suppliers to Australasia. More information can be found at
https://www.tearaibiofarma.com.au/microdox
About NuAngle
NuAngle was established in 1999 and has since built successful
partnerships with leading international companies with innovative
brands and products backed by clinical and scientific foundations.
NuAngle started as a medical device supplier in the urological
field but has since expanded into other medical markets (female and
male health, surgery, and wound care) as well as the specialized
aesthetics market. NuAngle strives to be the best medical device
and medical product supplier. NuAngle distributes products across
Southern Africa and outlying coastal islands. More information can
be found at www.nuangle.co.za/about-us/
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for
developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
animal health care, eye care, nasal care, oral care, and
dermatological conditions. The company’s products reduce
infections, itch, pain, scarring and harmful inflammatory responses
in a safe and effective manner. In-vitro and clinical studies of
hypochlorous acid (HOCl) show it to have impressive antipruritic,
antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s
stabilized HOCl immediately relieves itch and pain, kills pathogens
and breaks down biofilm, does not sting or irritate skin and
oxygenates the cells in the area treated assisting the body in its
natural healing process. The company’s products are sold either
directly or via partners in 54 countries worldwide and the company
actively seeks new distribution partners. The company’s principal
office is in Woodstock, Georgia, with manufacturing operations in
Latin America. European marketing and sales are headquartered in
Roermond, Netherlands. More information can be found at
www.sonomapharma.com. For partnership opportunities, please contact
busdev@sonomapharma.com
Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward-looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial and
technology progress and future financial performance of Sonoma
Pharmaceuticals, Inc. and its subsidiaries (the “company”). These
forward-looking statements are identified by the use of words such
as “continue,” “develop” and “expand,” among others.
Forward-looking statements in this press release are subject to
certain risks and uncertainties inherent in the company’s business
that could cause actual results to vary, including such risks that
regulatory clinical and guideline developments may change,
scientific data may not be sufficient to meet regulatory standards
or receipt of required regulatory clearances or approvals, clinical
results may not be replicated in actual patient settings,
protection offered by the company’s patents and patent applications
may be challenged, invalidated or circumvented by its competitors,
the available market for the company’s products will not be as
large as expected, the company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to meet the company’s cash needs, fund further
development, as well as uncertainties relative to the COVID-19
pandemic and economic development, varying product formulations and
a multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the company’s filings with the Securities and
Exchange Commission. The company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™, Microdox® and Microcyn® are trademarks
or registered trademarks of Sonoma Pharmaceuticals, Inc. All other
trademarks and service marks are the property of their respective
owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220330005223/en/
Media and Investor Contact: Sonoma Pharmaceuticals,
Inc. ir@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Apr 2023 to Apr 2024